Lexicon Pharmaceuticals Inc (LXRX)vsBeiGene, Ltd. (ONC)
LXRX
Lexicon Pharmaceuticals Inc
$2.00
-0.99%
HEALTHCARE · Cap: $1.01B
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 14680% more annual revenue ($6.13B vs $41.47M). ONC leads profitability with a 10.7% profit margin vs -147.4%. ONC earns a higher WallStSmart Score of 64/100 (C+).
LXRX
Avoid16
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LXRX.
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Smaller company, higher risk/reward
ROE of -12.9% — below average capital efficiency
Revenue declined 97.6%
Earnings declined 63.4%
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LXRX
LXRX has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : LXRX
The primary concerns for LXRX are Market Cap, Return on Equity, Revenue Growth.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
LXRX profiles as a turnaround stock while ONC is a growth play — different risk/reward profiles.
LXRX carries more volatility with a beta of 1.03 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 16/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lexicon Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?